OpenAI and the FDA are reportedly discussing AI for drug evaluations
OpenAi has met officials of the US Food and Drug Administration to discuss the use of AI through the agency to speed up drug evaluations, Wired On Wednesday.
According to the report, OpenAI and the FDA have discussed a project with the name Cdergpt, which seems to be an AI tool for the Center for Drug Evaluation (CDE). The CDE regulates freely available and prescribed medicines in the American employees of the Doge van Elon Musk, is reportedly also part of the conversations.
It is not uncommon that processes for developing medicines take more than a decade to complete. The work of OpenAi with the FDA wants to accelerate a small part of that timeline by the end, per wired. AI has long been promoted as a potentially acceleration that can be used during the development of medicines, so that some notoriously slow steps can become more efficient. That said, there are unanswered questions about how you can check for the unreliability of AI models.
